BRPI0917661B8 - produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina - Google Patents
produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclinaInfo
- Publication number
- BRPI0917661B8 BRPI0917661B8 BRPI0917661A BRPI0917661A BRPI0917661B8 BR PI0917661 B8 BRPI0917661 B8 BR PI0917661B8 BR PI0917661 A BRPI0917661 A BR PI0917661A BR PI0917661 A BRPI0917661 A BR PI0917661A BR PI0917661 B8 BRPI0917661 B8 BR PI0917661B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- macitentan
- product
- endowed
- combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001039 macitentan Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 102000009079 Epoprostenol Receptors Human genes 0.000 title 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 title 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229960001123 epoprostenol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2008053252 | 2008-08-13 | ||
| PCT/IB2009/053553 WO2010018549A2 (en) | 2008-08-13 | 2009-08-12 | Therapeutic compositions containing macitentan |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0917661A2 BRPI0917661A2 (pt) | 2015-12-01 |
| BRPI0917661B1 BRPI0917661B1 (pt) | 2019-12-17 |
| BRPI0917661B8 true BRPI0917661B8 (pt) | 2021-05-25 |
Family
ID=41346591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0917661A BRPI0917661B8 (pt) | 2008-08-13 | 2009-08-12 | produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8809334B2 (enExample) |
| EP (2) | EP3300729B1 (enExample) |
| JP (3) | JP5764061B2 (enExample) |
| KR (1) | KR101678699B1 (enExample) |
| CN (1) | CN102099026B (enExample) |
| AR (1) | AR073031A1 (enExample) |
| AU (1) | AU2009280843B2 (enExample) |
| BR (1) | BRPI0917661B8 (enExample) |
| CA (1) | CA2731370C (enExample) |
| CY (2) | CY1119826T1 (enExample) |
| DK (2) | DK3300729T3 (enExample) |
| ES (2) | ES2763176T3 (enExample) |
| HK (1) | HK1253355B (enExample) |
| HR (2) | HRP20171917T1 (enExample) |
| HU (2) | HUE047767T2 (enExample) |
| IL (1) | IL211143A0 (enExample) |
| LT (2) | LT3300729T (enExample) |
| MA (1) | MA32614B1 (enExample) |
| MX (1) | MX350011B (enExample) |
| MY (1) | MY178894A (enExample) |
| NO (1) | NO2315587T3 (enExample) |
| NZ (1) | NZ591601A (enExample) |
| PL (2) | PL3300729T3 (enExample) |
| PT (2) | PT2315587T (enExample) |
| RU (1) | RU2519161C2 (enExample) |
| SI (2) | SI3300729T1 (enExample) |
| SM (2) | SMT201900740T1 (enExample) |
| TW (1) | TWI446911B (enExample) |
| WO (1) | WO2010018549A2 (enExample) |
| ZA (1) | ZA201101900B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006290309B2 (en) | 2005-09-12 | 2012-04-05 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| JP5522030B2 (ja) | 2008-02-28 | 2014-06-18 | 日本新薬株式会社 | 線維化抑制剤 |
| NO2315587T3 (enExample) | 2008-08-13 | 2018-03-24 | ||
| JP6542128B2 (ja) | 2013-01-11 | 2019-07-10 | コルセア ファーマ インコーポレイテッド | トレプロスチニルのプロドラッグ |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9794795B1 (en) | 2016-04-29 | 2017-10-17 | Corning Optical Communications Wireless Ltd | Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS |
| JP2020502121A (ja) | 2016-12-14 | 2020-01-23 | レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 肺高血圧症および他の肺障害の処置のための方法および組成物 |
| AU2019339401B9 (en) * | 2018-09-14 | 2022-11-03 | Pharmosa Biopharm Inc. | Pharmaceutical composition for controlled release of weak acid drugs and uses thereof |
| BR112021011999A2 (pt) * | 2018-12-21 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Composição farmacêutica para o tratamento de hipertensão arterial pulmonar |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| US12485119B2 (en) | 2019-11-29 | 2025-12-02 | Actelion Pharmaceuticals Ltd | Methods of treating pulmonary arterial hypertension |
| US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
| CA3240614A1 (en) | 2021-12-31 | 2023-07-06 | Stuart Rich | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4539333A (en) * | 1976-05-11 | 1985-09-03 | Burroughs Wellcome Co. | Prostacyclin, methods of using and method of making |
| DE2845770A1 (de) * | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| US4683330A (en) | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| PT1345920E (pt) * | 2000-12-18 | 2006-08-31 | Actelion Pharmaceuticals Ltd | Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina |
| CN1481244A (zh) * | 2000-12-19 | 2004-03-10 | Ĭ��ר���ɷ�����˾ | 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂 |
| DE10100426B4 (de) | 2001-01-08 | 2006-04-06 | Steag Hamatech Ag | Verfahren und Vorrichtung zum Zusammenfügen von Substraten |
| TWI316055B (enExample) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2004017993A1 (en) * | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| BR0316724A (pt) * | 2002-12-02 | 2005-10-18 | Actelion Pharmaceuticals Ltd | Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| AU2006290309B2 (en) * | 2005-09-12 | 2012-04-05 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| AR062501A1 (es) * | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| US8541433B2 (en) * | 2008-02-20 | 2013-09-24 | Actelion Pharmaceuticals, Ltd. | Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer |
| NO2315587T3 (enExample) | 2008-08-13 | 2018-03-24 |
-
2009
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en not_active Ceased
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh not_active Expired - Fee Related
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt not_active IP Right Cessation
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 HR HRP20171917TT patent/HRP20171917T1/hr unknown
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 SM SM20190740T patent/SMT201900740T1/it unknown
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja not_active Expired - Fee Related
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active Active
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en not_active Revoked
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 SM SM20170592T patent/SMT201700592T1/it unknown
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/en active
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en not_active Revoked
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
-
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
-
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
-
2015
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
-
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/en not_active IP Right Cessation
-
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0917661B8 (pt) | produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina | |
| CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
| MX2009006304A (es) | Nuevos compuestos de oxadiazol. | |
| BRPI0708965B8 (pt) | composição farmacêutica de metilnaltrexona | |
| ECSP088623A (es) | Derivados de azepinoindol como agentes farmacéuticos | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
| MX384206B (es) | Formulaciones de inhibidores de dpp iv | |
| BRPI0916235B8 (pt) | composto, composição farmacêutica, e, uso do composto ou da composição | |
| MX2009000884A (es) | Derivados de piridizinona. | |
| WO2008021851A3 (en) | Novel compounds as antagonists or inverse agonists for opioid receptors | |
| BRPI0813218A2 (pt) | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. | |
| BR112013030939A2 (pt) | derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo | |
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| UY31736A (es) | Derivados sustituidos de pirazol y su uso | |
| GT200700064A (es) | Agonistas de ep2 | |
| EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| BRPI0615898B8 (pt) | composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável | |
| WO2007108936A3 (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
| WO2007136668A3 (en) | N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | |
| BRPI0715698B8 (pt) | produto, composição farmacêutica que o contém e uso de composto | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/12/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2787 DE 04-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |